ID   HIPK2_HUMAN             Reviewed;        1198 AA.
AC   Q9H2X6; Q75MR7; Q8WWI4; Q9H2Y1;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   06-JUN-2002, sequence version 2.
DT   15-MAR-2017, entry version 172.
DE   RecName: Full=Homeodomain-interacting protein kinase 2;
DE            Short=hHIPk2;
DE            EC=2.7.11.1;
GN   Name=HIPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF LYS-228.
RC   TISSUE=Liver, and Testis;
RX   PubMed=11267674; DOI=10.1016/S0167-4781(00)00308-0;
RA   Wang Y., Hofmann T.G., Runkel L., Haaf T., Schaller H., Debatin K.-M.,
RA   Hug H.;
RT   "Isolation and characterization of cDNAs for the protein kinase
RT   HIPK2.";
RL   Biochim. Biophys. Acta 1518:168-172(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Frontal cortex;
RA   Stukart G.C., Dias-Neto E.;
RT   "Sequencing of hHIPk2, a human homolog of mouse homeodomain
RT   interacting protein kinase 2.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 8-1198 (ISOFORM 2).
RA   Pierantoni G.M., Benvenuto G., Chiariotti L., Fusco A.;
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH TRADD.
RX   PubMed=11032752; DOI=10.1006/bbrc.2000.3700;
RA   Li X., Wang Y., Debatin K.-M., Hug H.;
RT   "The serine/threonine kinase HIPK2 interacts with TRADD, but not with
RT   CD95 or TNF-R1 in 293T cells.";
RL   Biochem. Biophys. Res. Commun. 277:513-517(2000).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=11798164; DOI=10.1006/bbrc.2001.6310;
RA   Pierantoni G.M., Bulfone A., Pentimalli F., Fedele M., Iuliano R.,
RA   Santoro M., Chiariotti L., Ballabio A., Fusco A.;
RT   "The homeodomain-interacting protein kinase 2 gene is expressed late
RT   in embryogenesis and preferentially in retina, muscle, and neural
RT   tissues.";
RL   Biochem. Biophys. Res. Commun. 290:942-947(2002).
RN   [7]
RP   INTERACTION WITH RANBP9, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-228.
RX   PubMed=12220523; DOI=10.1016/S0006-291X(02)02020-X;
RA   Wang Y., Marion Schneider E., Li X., Duttenhoefer I., Debatin K.-M.,
RA   Hug H.;
RT   "HIPK2 associates with RanBPM.";
RL   Biochem. Biophys. Res. Commun. 297:148-153(2002).
RN   [8]
RP   INTERACTION WITH TP73; TP53 AND TP63, MUTAGENESIS OF LYS-228, AND
RP   FUNCTION.
RX   PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [9]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, INTERACTION WITH TP53 AND
RP   CREBBP, MUTAGENESIS OF LYS-228, FUNCTION, AND INDUCTION.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-228.
RX   PubMed=12907596;
RA   Moeller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E.,
RA   Droege W., Will H., Schmitz M.L.;
RT   "PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-
RT   mediated p53 phosphorylation and cell cycle arrest but is dispensable
RT   for the formation of HIPK domains.";
RL   Cancer Res. 63:4310-4314(2003).
RN   [11]
RP   FUNCTION, INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-228.
RX   PubMed=14678985;
RA   Hofmann T.G., Stollberg N., Schmitz M.L., Will H.;
RT   "HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-
RT   terminal kinase activation and apoptosis in human hepatoma cells.";
RL   Cancer Res. 63:8271-8277(2003).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH P53DINP1.
RX   PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [13]
RP   FUNCTION, INTERACTION WITH SKI; SMAD1; SMAD2 AND SMAD3, AND
RP   MUTAGENESIS OF LYS-228 AND 359-SER--TYR-361.
RX   PubMed=12874272; DOI=10.1074/jbc.M307112200;
RA   Harada J., Kokura K., Kanei-Ishii C., Nomura T., Khan M.M., Kim Y.,
RA   Ishii S.;
RT   "Requirement of the co-repressor homeodomain-interacting protein
RT   kinase 2 for ski-mediated inhibition of bone morphogenetic protein-
RT   induced transcriptional activation.";
RL   J. Biol. Chem. 278:38998-39005(2003).
RN   [14]
RP   INTERACTION WITH SP100.
RX   PubMed=14647468; DOI=10.1038/sj.onc.1207079;
RA   Moeller A., Sirma H., Hofmann T.G., Staege H., Gresko E., Luedi K.S.,
RA   Klimczak E., Droege W., Will H., Schmitz M.L.;
RT   "Sp100 is important for the stimulatory effect of homeodomain-
RT   interacting protein kinase-2 on p53-dependent gene expression.";
RL   Oncogene 22:8731-8737(2003).
RN   [15]
RP   DESUMOYLATION.
RX   PubMed=16253240; DOI=10.1016/j.febslet.2005.10.010;
RA   Kim Y.H., Sung K.S., Lee S.-J., Kim Y.-O., Choi C.Y., Kim Y.;
RT   "Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2)
RT   through the cytoplasmic-nuclear shuttling of the SUMO-specific
RT   protease SENP1.";
RL   FEBS Lett. 579:6272-6278(2005).
RN   [16]
RP   CLEAVAGE BY CASP6 AT ASP-923 AND ASP-984.
RX   PubMed=16601678; DOI=10.1038/sj.emboj.7601077;
RA   Gresko E., Roscic A., Ritterhoff S., Vichalkovski A., del Sal G.,
RA   Schmitz M.L.;
RT   "Autoregulatory control of the p53 response by caspase-mediated
RT   processing of HIPK2.";
RL   EMBO J. 25:1883-1894(2006).
RN   [17]
RP   INTERACTION WITH CBX4, SUMOYLATION AT LYS-32, AND FUNCTION.
RX   PubMed=17018294; DOI=10.1016/j.molcel.2006.08.004;
RA   Roscic A., Moeller A., Calzado M.A., Renner F., Wimmer V.C.,
RA   Gresko E., Luedi K.S., Schmitz M.L.;
RT   "Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by
RT   its substrate protein HIPK2.";
RL   Mol. Cell 24:77-89(2006).
RN   [18]
RP   FUNCTION AS HMGA1 KINASE.
RX   PubMed=17960875; DOI=10.1021/pr700571d;
RA   Zhang Q., Wang Y.;
RT   "Homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates
RT   HMGA1a at Ser-35, Thr-52, and Thr-77 and modulates its DNA binding
RT   affinity.";
RL   J. Proteome Res. 6:4711-4719(2007).
RN   [19]
RP   FUNCTION AS RUNX1 AND EP300 KINASE, AND MUTAGENESIS OF LYS-228.
RX   PubMed=18695000; DOI=10.1182/blood-2008-01-134122;
RA   Wee H.-J., Voon D.C.-C., Bae S.-C., Ito Y.;
RT   "PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by
RT   HIPK2: implications for leukemogenesis.";
RL   Blood 112:3777-3787(2008).
RN   [20]
RP   INTERACTION WITH WSB1, AND UBIQUITINATION BY WSB1.
RX   PubMed=18093972; DOI=10.1074/jbc.M708873200;
RA   Choi D.W., Seo Y.-M., Kim E.-A., Sung K.S., Ahn J.W., Park S.-J.,
RA   Lee S.-R., Choi C.Y.;
RT   "Ubiquitination and degradation of homeodomain-interacting protein
RT   kinase 2 by WD40 repeat/SOCS box protein WSB-1.";
RL   J. Biol. Chem. 283:4682-4689(2008).
RN   [21]
RP   FUNCTION, AND UBIQUITINATION BY FBXO3.
RX   PubMed=18809579; DOI=10.1128/MCB.00897-08;
RA   Shima Y., Shima T., Chiba T., Irimura T., Pandolfi P.P.,
RA   Kitabayashi I.;
RT   "PML activates transcription by protecting HIPK2 and p300 from
RT   SCFFbx3-mediated degradation.";
RL   Mol. Cell. Biol. 28:7126-7138(2008).
RN   [22]
RP   INDUCTION BY DNA DAMAGE, INTERACTION WITH SIAH1, AND UBIQUITINATION BY
RP   SIAH1.
RX   PubMed=18536714; DOI=10.1038/ncb1743;
RA   Winter M., Sombroek D., Dauth I., Moehlenbrink J., Scheuermann K.,
RA   Crone J., Hofmann T.G.;
RT   "Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint
RT   kinases ATM and ATR.";
RL   Nat. Cell Biol. 10:812-824(2008).
RN   [23]
RP   FUNCTION AS HIF1A TRANSCRIPTION REGULATOR AND ANGIOGENESIS PROMOTER.
RX   PubMed=19046997; DOI=10.1016/j.bbamcr.2008.10.013;
RA   Nardinocchi L., Puca R., Guidolin D., Belloni A.S., Bossi G.,
RA   Michiels C., Sacchi A., Onisto M., D'Orazi G.;
RT   "Transcriptional regulation of hypoxia-inducible factor 1alpha by
RT   HIPK2 suggests a novel mechanism to restrain tumor growth.";
RL   Biochim. Biophys. Acta 1793:368-377(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   FUNCTION AS PML KINASE, INTERACTION WITH PML, AND MUTAGENESIS OF
RP   LYS-228.
RX   PubMed=19015637; DOI=10.1038/onc.2008.420;
RA   Gresko E., Ritterhoff S., Sevilla-Perez J., Roscic A., Froebius K.,
RA   Kotevic I., Vichalkovski A., Hess D., Hemmings B.A., Schmitz M.L.;
RT   "PML tumor suppressor is regulated by HIPK2-mediated phosphorylation
RT   in response to DNA damage.";
RL   Oncogene 28:698-708(2009).
RN   [26]
RP   FUNCTION AS ZBTB4 KINASE, AND INTERACTION WITH ZBTB4.
RX   PubMed=19448668; DOI=10.1038/onc.2009.109;
RA   Yamada D., Perez-Torrado R., Filion G., Caly M., Jammart B.,
RA   Devignot V., Sasai N., Ravassard P., Mallet J., Sastre-Garau X.,
RA   Schmitz M.L., Defossez P.A.;
RT   "The human protein kinase HIPK2 phosphorylates and downregulates the
RT   methyl-binding transcription factor ZBTB4.";
RL   Oncogene 28:2535-2544(2009).
RN   [27]
RP   INDUCTION BY ZINC DURING HYPOXIA.
RX   PubMed=19714248; DOI=10.1371/journal.pone.0006819;
RA   Nardinocchi L., Puca R., Sacchi A., Rechavi G., Givol D., D'Orazi G.;
RT   "Targeting hypoxia in cancer cells by restoring homeodomain
RT   interacting protein-kinase 2 and p53 activity and suppressing HIF-
RT   1alpha.";
RL   PLoS ONE 4:E6819-E6819(2009).
RN   [28]
RP   FUNCTION AS PDX1 KINASE.
RX   PubMed=20637728; DOI=10.1016/j.bbrc.2010.07.035;
RA   An R., da Silva Xavier G., Semplici F., Vakhshouri S., Hao H.X.,
RA   Rutter J., Pagano M.A., Meggio F., Pinna L.A., Rutter G.A.;
RT   "Pancreatic and duodenal homeobox 1 (PDX1) phosphorylation at serine-
RT   269 is HIPK2-dependent and affects PDX1 subnuclear localization.";
RL   Biochem. Biophys. Res. Commun. 399:155-161(2010).
RN   [29]
RP   FUNCTION AS CTNNB1 KINASE.
RX   PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099;
RA   Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.;
RT   "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin
RT   for phosphorylation and proteasomal degradation.";
RL   Biochem. Biophys. Res. Commun. 394:966-971(2010).
RN   [30]
RP   FUNCTION AS ATF1 KINASE, AND INTERACTION WITH ATF1.
RX   PubMed=20980392; DOI=10.1242/jcs.073627;
RA   Hailemariam K., Iwasaki K., Huang B.W., Sakamoto K., Tsuji Y.;
RT   "Transcriptional regulation of ferritin and antioxidant genes by HIPK2
RT   under genotoxic stress.";
RL   J. Cell Sci. 123:3863-3871(2010).
RN   [31]
RP   FUNCTION AS CREB1 KINASE, AND INTERACTION WITH CREB1.
RX   PubMed=20573984; DOI=10.1091/mbc.E10-01-0015;
RA   Sakamoto K., Huang B.-W., Iwasaki K., Hailemariam K.,
RA   Ninomiya-Tsuji J., Tsuji Y.;
RT   "Regulation of genotoxic stress response by homeodomain-interacting
RT   protein kinase 2 through phosphorylation of cyclic AMP response
RT   element-binding protein at serine 271.";
RL   Mol. Biol. Cell 21:2966-2974(2010).
RN   [32]
RP   SUBCELLULAR LOCATION, SUMOYLATION, NUCLEAR LOCALIZATION SIGNALS,
RP   MUTAGENESIS OF LYS-803; LYS-805; ARG-833; LYS-835; 885-VAL--SER-892
RP   AND 893-ASP--GLU-899, AND INTERACTION WITH CBX4.
RX   PubMed=21145359; DOI=10.1016/j.bbamcr.2010.11.022;
RA   de la Vega L., Froebius K., Moreno R., Calzado M.A., Geng H.,
RA   Schmitz M.L.;
RT   "Control of nuclear HIPK2 localization and function by a SUMO
RT   interaction motif.";
RL   Biochim. Biophys. Acta 1813:283-297(2011).
RN   [33]
RP   SUBCELLULAR LOCATION, SUMOYLATION, FUNCTION, AND MUTAGENESIS OF
RP   885-VAL--ILE-888 AND 892-SER--ASP-895.
RX   PubMed=21192925; DOI=10.1016/j.yexcr.2010.12.016;
RA   Sung K.S., Lee Y.A., Kim E.T., Lee S.R., Ahn J.H., Choi C.Y.;
RT   "Role of the SUMO-interacting motif in HIPK2 targeting to the PML
RT   nuclear bodies and regulation of p53.";
RL   Exp. Cell Res. 317:1060-1070(2011).
RN   [34]
RP   REVIEW ON DNA DAMAGE SIGNALING, INDUCTION BY GENOTOXIC AGENTS, AND
RP   STABILIZATION BY DNA DAMAGE.
RX   PubMed=18974774; DOI=10.1038/cdd.2008.154;
RA   Sombroek D., Hofmann T.G.;
RT   "How cells switch HIPK2 on and off.";
RL   Cell Death Differ. 16:187-194(2009).
RN   [35]
RP   REVIEW.
RX   PubMed=19788416; DOI=10.1111/j.1742-4658.2009.07331.x;
RA   Bitomsky N., Hofmann T.G.;
RT   "Apoptosis and autophagy: Regulation of apoptosis by DNA damage
RT   signalling - roles of p53, p73 and HIPK2.";
RL   FEBS J. 276:6074-6083(2009).
RN   [36]
RP   REVIEW AS HYPOXIA AND TP53 REGULATOR.
RX   PubMed=20234185; DOI=10.4161/cc.9.7.11125;
RA   Nardinocchi L., Puca R., Givol D., D'Orazi G.;
RT   "HIPK2-a therapeutical target to be (re)activated for tumor
RT   suppression: role in p53 activation and HIF-1? inhibition.";
RL   Cell Cycle 9:1270-1275(2010).
RN   [37]
RP   REVIEW AS TP53 REGULATOR, AND INDUCTION BY GENOTOXIC AGENTS AND
RP   HYPOXIA.
RX   PubMed=20514025; DOI=10.1038/onc.2010.183;
RA   Puca R., Nardinocchi L., Givol D., D'Orazi G.;
RT   "Regulation of p53 activity by HIPK2: molecular mechanisms and
RT   therapeutical implications in human cancer cells.";
RL   Oncogene 29:4378-4387(2010).
RN   [38]
RP   FUNCTION.
RX   PubMed=22825850; DOI=10.1074/jbc.M112.390120;
RA   Pelisch F., Pozzi B., Risso G., Munoz M.J., Srebrow A.;
RT   "DNA damage-induced heterogeneous nuclear ribonucleoprotein K
RT   SUMOylation regulates p53 transcriptional activation.";
RL   J. Biol. Chem. 287:30789-30799(2012).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-792 AND GLN-1027.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in
CC       transcription regulation, p53/TP53-mediated cellular apoptosis and
CC       regulation of the cell cycle. Acts as a corepressor of several
CC       transcription factors, including SMAD1 and POU4F1/Brn3a and
CC       probably NK homeodomain transcription factors. Phosphorylates
CC       PDX1, ATF1, PML, p53/TP53, CREB1, CTBP1, CBX4, RUNX1, EP300,
CC       CTNNB1, HMGA1 and ZBTB4. Inhibits cell growth and promotes
CC       apoptosis through the activation of p53/TP53 both at the
CC       transcription level and at the protein level (by phosphorylation
CC       and indirect acetylation). The phosphorylation of p53/TP53 may be
CC       mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in the
CC       response to hypoxia by acting as a transcriptional co-suppressor
CC       of HIF1A. Mediates transcriptional activation of TP73. In response
CC       to TGFB, cooperates with DAXX to activate JNK. Negative regulator
CC       through phosphorylation and subsequent proteasomal degradation of
CC       CTNNB1 and the antiapoptotic factor CTBP1. In the Wnt/beta-catenin
CC       signaling pathway acts as an intermediate kinase between
CC       MAP3K7/TAK1 and NLK to promote the proteasomal degradation of MYB.
CC       Phosphorylates CBX4 upon DNA damage and promotes its E3 SUMO-
CC       protein ligase activity. Activates CREB1 and ATF1 transcription
CC       factors by phosphorylation in response to genotoxic stress. In
CC       response to DNA damage, stabilizes PML by phosphorylation. PML,
CC       HIPK2 and FBXO3 may act synergically to activate p53/TP53-
CC       dependent transactivation. Promotes angiogenesis, and is involved
CC       in erythroid differentiation, especially during fetal liver
CC       erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates
CC       EP300 transcription regulation activity. Triggers ZBTB4 protein
CC       degradation in response to DNA damage. Modulates HMGA1 DNA-binding
CC       affinity. In response to high glucose, triggers phosphorylation-
CC       mediated subnuclear localization shifting of PDX1. Involved in the
CC       regulation of eye size, lens formation and retinal lamination
CC       during late embryogenesis. {ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12851404,
CC       ECO:0000269|PubMed:12874272, ECO:0000269|PubMed:14678985,
CC       ECO:0000269|PubMed:17018294, ECO:0000269|PubMed:17960875,
CC       ECO:0000269|PubMed:18695000, ECO:0000269|PubMed:18809579,
CC       ECO:0000269|PubMed:19015637, ECO:0000269|PubMed:19046997,
CC       ECO:0000269|PubMed:19448668, ECO:0000269|PubMed:20307497,
CC       ECO:0000269|PubMed:20573984, ECO:0000269|PubMed:20637728,
CC       ECO:0000269|PubMed:20980392, ECO:0000269|PubMed:21192925,
CC       ECO:0000269|PubMed:22825850}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with CREB1, SIAH1, WSB1, CBX4, TRADD, p53/TP53,
CC       TP73, TP63, CREBBP, DAXX, P53DINP1, SKI, SMAD1, SMAD2 and SMAD3,
CC       but not SMAD4. Interacts with ATF1, PML, RUNX1, EP300, NKX1-2,
CC       NKX2-5, SPN/CD43, UBE2I, HMGA1, CTBP1, AXIN1, NLK, MYB, POU4F1,
CC       POU4F2, POU4F3, UBE2I, UBL1 and ZBTB4. Probably part of a complex
CC       consisting of p53/TP53, HIPK2 and AXIN1. Interacts with SP100;
CC       positively regulates TP53-dependent transcription.
CC       {ECO:0000269|PubMed:11032752, ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12220523,
CC       ECO:0000269|PubMed:12851404, ECO:0000269|PubMed:12874272,
CC       ECO:0000269|PubMed:14647468, ECO:0000269|PubMed:14678985,
CC       ECO:0000269|PubMed:17018294, ECO:0000269|PubMed:18093972,
CC       ECO:0000269|PubMed:18536714, ECO:0000269|PubMed:19015637,
CC       ECO:0000269|PubMed:19448668, ECO:0000269|PubMed:20573984,
CC       ECO:0000269|PubMed:20980392, ECO:0000269|PubMed:21145359}.
CC   -!- INTERACTION:
CC       P61962:DCAF7; NbExp=10; IntAct=EBI-348345, EBI-359808;
CC       Q09472:EP300; NbExp=4; IntAct=EBI-348345, EBI-447295;
CC       P51608:MECP2; NbExp=2; IntAct=EBI-348345, EBI-1189067;
CC       Q01196:RUNX1; NbExp=4; IntAct=EBI-348345, EBI-925904;
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body. Cytoplasm.
CC       Note=Concentrated in PML/POD/ND10 nuclear bodies. Small amounts
CC       are cytoplasmic.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Experimental confirmation may be lacking for some
CC         isoforms.;
CC       Name=1;
CC         IsoId=Q9H2X6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H2X6-2; Sequence=VSP_004805, VSP_004806, VSP_004807;
CC       Name=3;
CC         IsoId=Q9H2X6-3; Sequence=VSP_004804;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, muscle and kidney.
CC       Weakly expressed in a ubiquitous way. Down-regulated in several
CC       thyroid and breast tumors. {ECO:0000269|PubMed:11267674,
CC       ECO:0000269|PubMed:11798164}.
CC   -!- INDUCTION: Unstable in unstressed cells but stabilized upon DNA
CC       damage. Induced by UV irradiation and other genotoxic agents
CC       (adriamycin ADR, cisplatin CDDP, etoposide, IR, roscovitin), thus
CC       triggering p53/TP53 apoptotic response. Consistutively negatively
CC       regulated by SIAH1 and WSB1 through proteasomal degradation. This
CC       negative regulation is impaired upon genotoxic stress. Repressed
CC       upon hypoxia (often associated with tumors), through MDM2- (an E3
CC       ubiquitin ligases) mediated proteasomal degradation, thus
CC       inactivating p53/TP53 apoptotic response. This hypoxia repression
CC       is reversed by zinc. The stabilization mediated by DNA damage
CC       requires the damage checkpoint kinases ATM and ATR.
CC       {ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:18536714,
CC       ECO:0000269|PubMed:18974774, ECO:0000269|PubMed:19714248,
CC       ECO:0000269|PubMed:20514025}.
CC   -!- PTM: Autophosphorylation at Tyr-361 in the activation loop
CC       activates the kinase and promotes nuclear localization.
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylated. When conjugated it is directed to nuclear
CC       speckles. Desumoylated by SENP1 (By similarity). Sumoylation on
CC       Lys-32 is promoted by the E3 SUMO-protein ligase CBX4.
CC       {ECO:0000250, ECO:0000269|PubMed:16253240,
CC       ECO:0000269|PubMed:17018294, ECO:0000269|PubMed:21145359,
CC       ECO:0000269|PubMed:21192925}.
CC   -!- PTM: Ubiquitinated by FBXO3, WSB1 and SIAH1, leading to rapid
CC       proteasome-dependent degradation. The degradation mediated by
CC       FBXO3, but not ubiquitination, is prevented in the presence of
CC       PML. The degradation mediated by WSB1 and SIAH1 is reversibly
CC       reduced upon DNA damage. {ECO:0000269|PubMed:18093972,
CC       ECO:0000269|PubMed:18536714, ECO:0000269|PubMed:18809579}.
CC   -!- PTM: Cleaved at Asp-923 and Asp-984 by CASP6 in a p53/TP53-
CC       dependent manner. The cleaved form lacks the autoinhibitory C-
CC       terminal domain (AID), resulting in a hyperactive kinase, which
CC       potentiates p53/TP53 Ser-46 phosphorylation and subsequent
CC       activation of the cell death machinery.
CC       {ECO:0000269|PubMed:16601678}.
CC   -!- MISCELLANEOUS: Interesting targets for cancer therapy. HIPK2
CC       deregulation would end up in a multifactorial response leading to
CC       tumor chemoresistance by affecting p53/TP53 activity on one hand
CC       and to angiogenesis and cell proliferation by affecting HIF1A
CC       activity on the other hand. May provide important insights in the
CC       process of tumor progression, and may also serve as the crucial
CC       point in the diagnostic and therapeutical aspects of cancer. Tumor
CC       treatment may potential be improved by zinc supplementation in
CC       combination with chemotherapy to address hypoxia
CC       (PubMed:20514025). {ECO:0000305|PubMed:20514025}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. HIPK subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HIPK2ID40824ch7q34.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF208291; AAG41236.1; -; mRNA.
DR   EMBL; AF326592; AAL37371.1; -; mRNA.
DR   EMBL; AC005531; AAS00368.1; -; Genomic_DNA.
DR   EMBL; AC073184; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006021; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC141932; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF207702; AAG35710.1; -; mRNA.
DR   CCDS; CCDS75666.1; -. [Q9H2X6-3]
DR   CCDS; CCDS75667.1; -. [Q9H2X6-1]
DR   RefSeq; NP_001106710.1; NM_001113239.2. [Q9H2X6-3]
DR   RefSeq; NP_073577.3; NM_022740.4. [Q9H2X6-1]
DR   UniGene; Hs.731417; -.
DR   ProteinModelPortal; Q9H2X6; -.
DR   SMR; Q9H2X6; -.
DR   BioGrid; 118815; 60.
DR   DIP; DIP-31716N; -.
DR   IntAct; Q9H2X6; 19.
DR   MINT; MINT-234689; -.
DR   STRING; 9606.ENSP00000385571; -.
DR   BindingDB; Q9H2X6; -.
DR   ChEMBL; CHEMBL4576; -.
DR   GuidetoPHARMACOLOGY; 2034; -.
DR   iPTMnet; Q9H2X6; -.
DR   PhosphoSitePlus; Q9H2X6; -.
DR   BioMuta; HIPK2; -.
DR   DMDM; 21431782; -.
DR   MaxQB; Q9H2X6; -.
DR   PaxDb; Q9H2X6; -.
DR   PeptideAtlas; Q9H2X6; -.
DR   PRIDE; Q9H2X6; -.
DR   TopDownProteomics; Q9H2X6-2; -. [Q9H2X6-2]
DR   DNASU; 28996; -.
DR   Ensembl; ENST00000406875; ENSP00000385571; ENSG00000064393. [Q9H2X6-1]
DR   Ensembl; ENST00000428878; ENSP00000413724; ENSG00000064393. [Q9H2X6-3]
DR   GeneID; 28996; -.
DR   KEGG; hsa:28996; -.
DR   UCSC; uc003vvd.5; human. [Q9H2X6-1]
DR   CTD; 28996; -.
DR   DisGeNET; 28996; -.
DR   GeneCards; HIPK2; -.
DR   HGNC; HGNC:14402; HIPK2.
DR   HPA; HPA007611; -.
DR   MIM; 606868; gene.
DR   neXtProt; NX_Q9H2X6; -.
DR   OpenTargets; ENSG00000064393; -.
DR   PharmGKB; PA29291; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   eggNOG; ENOG410XPET; LUCA.
DR   GeneTree; ENSGT00760000119032; -.
DR   HOGENOM; HOG000231785; -.
DR   HOVERGEN; HBG051908; -.
DR   InParanoid; Q9H2X6; -.
DR   KO; K08826; -.
DR   OMA; MIQNNAS; -.
DR   OrthoDB; EOG091G0UMX; -.
DR   PhylomeDB; Q9H2X6; -.
DR   TreeFam; TF105417; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-5578768; Physiological factors.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q9H2X6; -.
DR   SIGNOR; Q9H2X6; -.
DR   ChiTaRS; HIPK2; human.
DR   GeneWiki; HIPK2; -.
DR   GenomeRNAi; 28996; -.
DR   PMAP-CutDB; Q9H2X6; -.
DR   PRO; PR:Q9H2X6; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000064393; -.
DR   CleanEx; HS_HIPK2; -.
DR   ExpressionAtlas; Q9H2X6; baseline and differential.
DR   Genevisible; Q9H2X6; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:BHF-UCL.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0046332; F:SMAD binding; IPI:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0046790; F:virion binding; IPI:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; TAS:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:BHF-UCL.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0060059; P:embryonic retina morphogenesis in camera-type eye; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0001654; P:eye development; ISS:UniProtKB.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; NAS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; TAS:UniProtKB.
DR   GO; GO:0061072; P:iris morphogenesis; IEA:Ensembl.
DR   GO; GO:0060235; P:lens induction in camera-type eye; IEA:Ensembl.
DR   GO; GO:0019048; P:modulation by virus of host morphology or physiology; NAS:UniProtKB.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0030578; P:PML body organization; TAS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISS:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0010842; P:retina layer formation; IEA:Ensembl.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; ATP-binding; Complete proteome;
KW   Cytoplasm; DNA damage; Isopeptide bond; Kinase; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1   1198       Homeodomain-interacting protein kinase 2.
FT                                /FTId=PRO_0000085995.
FT   DOMAIN      199    527       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     205    213       ATP. {ECO:0000305}.
FT   REGION       97    230       Transcriptional corepression.
FT                                {ECO:0000250}.
FT   REGION      189    520       Interaction with DAXX.
FT                                {ECO:0000269|PubMed:14678985}.
FT   REGION      539    844       Interaction with SKI and SMAD1.
FT                                {ECO:0000269|PubMed:12874272}.
FT   REGION      752    897       Interaction with POU4F1. {ECO:0000250}.
FT   REGION      774    876       Interaction with CTBP1. {ECO:0000250}.
FT   REGION      787    897       Interaction with HMGA1. {ECO:0000250}.
FT   REGION      846    941       Interaction with TP53 and TP73.
FT                                {ECO:0000269|PubMed:11925430}.
FT   REGION      873    980       Required for localization to nuclear
FT                                speckles. {ECO:0000250}.
FT   REGION      873    907       Interaction with UBE2I. {ECO:0000250}.
FT   REGION      884    908       SUMO interaction motifs (SIM); required
FT                                for nuclear localization and kinase
FT                                activity.
FT   REGION      935   1049       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      984   1198       Autoinhibitory domain (AID).
FT   MOTIF       802    805       Nuclear localization signal 1 (NLS1).
FT   MOTIF       832    835       Nuclear localization signal 2 (NLS2).
FT   COMPBIAS   1088   1094       Poly-Ala.
FT   ACT_SITE    324    324       Proton acceptor. {ECO:0000305}.
FT   BINDING     228    228       ATP. {ECO:0000305}.
FT   SITE        923    924       Cleavage; by CASP6.
FT   SITE        984    985       Cleavage; by CASP6.
FT   MOD_RES      16     16       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     118    118       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     135    135       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     141    141       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     252    252       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     273    273       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     361    361       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     441    441       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     482    482       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     517    517       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     566    566       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     634    634       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     687    687       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     815    815       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     827    827       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     934    934       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES     992    992       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES    1041   1041       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES    1155   1155       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   MOD_RES    1188   1188       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QZR5}.
FT   CROSSLNK     32     32       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:17018294}.
FT   CROSSLNK   1191   1191       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ     595    621       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_004804.
FT   VAR_SEQ     808    907       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_004805.
FT   VAR_SEQ     989   1018       VNTSHHSSSYKSKSSSNVTSTSGHSSGSSS -> GNLGPGQ
FT                                GRNLSLESGFPAFLLLEMLLYGS (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_004806.
FT   VAR_SEQ    1019   1198       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_004807.
FT   VARIANT     792    792       R -> Q (in dbSNP:rs56132157).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040547.
FT   VARIANT    1027   1027       R -> Q (in dbSNP:rs35255718).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040548.
FT   MUTAGEN     228    228       K->A: Locates in the nucleoplasm, no
FT                                effect on interaction with RANBP9, but
FT                                loss of kinase activity toward PML, RUNX1
FT                                and EP300. {ECO:0000269|PubMed:11267674,
FT                                ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:11925430,
FT                                ECO:0000269|PubMed:12220523,
FT                                ECO:0000269|PubMed:12874272,
FT                                ECO:0000269|PubMed:12907596,
FT                                ECO:0000269|PubMed:14678985,
FT                                ECO:0000269|PubMed:18695000,
FT                                ECO:0000269|PubMed:19015637}.
FT   MUTAGEN     228    228       K->R: Abolishes enzymatic activity, no
FT                                effect on interaction with TP53 and TP73
FT                                or on BMP-induced transcriptional
FT                                activation. Enhances BMP-induced
FT                                transcriptional activation; when
FT                                associated with 359-AAF-361.
FT                                {ECO:0000269|PubMed:11267674,
FT                                ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:11925430,
FT                                ECO:0000269|PubMed:12220523,
FT                                ECO:0000269|PubMed:12874272,
FT                                ECO:0000269|PubMed:12907596,
FT                                ECO:0000269|PubMed:14678985,
FT                                ECO:0000269|PubMed:18695000,
FT                                ECO:0000269|PubMed:19015637}.
FT   MUTAGEN     359    361       STY->AAF: Enhances BMP-induced
FT                                transcriptional activation; when
FT                                associated with R-228.
FT                                {ECO:0000269|PubMed:12874272}.
FT   MUTAGEN     803    803       K->A: Impaired nuclear localization; when
FT                                associated with A-805.
FT                                {ECO:0000269|PubMed:21145359}.
FT   MUTAGEN     805    805       K->A: Impaired nuclear localization; when
FT                                associated with A-803.
FT                                {ECO:0000269|PubMed:21145359}.
FT   MUTAGEN     833    833       R->A: Impaired nuclear localization.
FT                                {ECO:0000269|PubMed:21145359}.
FT   MUTAGEN     835    835       K->E: Impaired nuclear localization.
FT                                {ECO:0000269|PubMed:21145359}.
FT   MUTAGEN     885    892       VSVITISS->KFMHFHRM: Loss of SUMO and CBX4
FT                                interaction, and impaired nuclear and
FT                                PML-nuclear bodies localization.
FT                                {ECO:0000269|PubMed:21145359}.
FT   MUTAGEN     885    888       VSVI->KSAK: Loss of SUMO interaction, and
FT                                impaired nuclear and PML-nuclear bodies
FT                                localization.
FT                                {ECO:0000269|PubMed:21192925}.
FT   MUTAGEN     892    895       SDTD->ADTA: Loss of SUMO interaction, and
FT                                impaired nuclear and PML-nuclear bodies
FT                                localization.
FT                                {ECO:0000269|PubMed:21192925}.
FT   MUTAGEN     893    899       DTDEEEE->NFNQQQQ: Loss of SUMO and CBX4
FT                                interaction, and impaired nuclear and
FT                                PML-nuclear bodies localization.
FT                                {ECO:0000269|PubMed:21145359}.
FT   CONFLICT     33     33       I -> V (in Ref. 1; AAG41236).
FT                                {ECO:0000305}.
FT   CONFLICT     59     59       L -> P (in Ref. 1; AAG41236).
FT                                {ECO:0000305}.
FT   CONFLICT     64     64       T -> S (in Ref. 1; AAG41236).
FT                                {ECO:0000305}.
FT   CONFLICT    169    169       S -> F (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
FT   CONFLICT    187    187       V -> S (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
FT   CONFLICT    202    202       L -> S (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
FT   CONFLICT    233    233       H -> R (in Ref. 1; AAG41236).
FT                                {ECO:0000305}.
FT   CONFLICT    471    471       N -> I (in Ref. 2; AAL37371).
FT                                {ECO:0000305}.
FT   CONFLICT    669    669       P -> S (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
FT   CONFLICT    711    711       T -> N (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
FT   CONFLICT    717    719       PPA -> SPT (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
FT   CONFLICT    724    724       T -> D (in Ref. 4; AAG35710).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1198 AA;  130966 MW;  6022D5710E8D2D93 CRC64;
     MAPVYEGMAS HVQVFSPHTL QSSAFCSVKK LKIEPSSNWD MTGYGSHSKV YSQSKNIPLS
     QPATTTVSTS LPVPNPSLPY EQTIVFPGST GHIVVTSASS TSVTGQVLGG PHNLMRRSTV
     SLLDTYQKCG LKRKSEEIEN TSSVQIIEEH PPMIQNNASG ATVATATTST ATSKNSGSNS
     EGDYQLVQHE VLCSMTNTYE VLEFLGRGTF GQVVKCWKRG TNEIVAIKIL KNHPSYARQG
     QIEVSILARL STESADDYNF VRAYECFQHK NHTCLVFEML EQNLYDFLKQ NKFSPLPLKY
     IRPVLQQVAT ALMKLKSLGL IHADLKPENI MLVDPSRQPY RVKVIDFGSA SHVSKAVCST
     YLQSRYYRAP EIILGLPFCE AIDMWSLGCV IAELFLGWPL YPGASEYDQI RYISQTQGLP
     AEYLLSAGTK TTRFFNRDTD SPYPLWRLKT PDDHEAETGI KSKEARKYIF NCLDDMAQVN
     MTTDLEGSDM LVEKADRREF IDLLKKMLTI DADKRITPIE TLNHPFVTMT HLLDFPHSTH
     VKSCFQNMEI CKRRVNMYDT VNQSKTPFIT HVAPSTSTNL TMTFNNQLTT VHNQAPSSTS
     ATISLANPEV SILNYPSTLY QPSAASMAAV AQRSMPLQTG TAQICARPDP FQQALIVCPP
     GFQGLQASPS KHAGYSVRME NAVPIVTQAP GAQPLQIQPG LLAQQAWPSG TQQILLPPAW
     QQLTGVATHT SVQHATVIPE TMAGTQQLAD WRNTHAHGSH YNPIMQQPAL LTGHVTLPAA
     QPLNVGVAHV MRQQPTSTTS SRKSKQHQSS VRNVSTCEVS SSQAISSPQR SKRVKENTPP
     RCAMVHSSPA CSTSVTCGWG DVASSTTRER QRQTIVIPDT PSPTVSVITI SSDTDEEEEQ
     KHAPTSTVSK QRKNVISCVT VHDSPYSDSS SNTSPYSVQQ RAGHNNANAF DTKGSLENHC
     TGNPRTIIVP PLKTQASEVL VECDSLVPVN TSHHSSSYKS KSSSNVTSTS GHSSGSSSGA
     ITYRQQRPGP HFQQQQPLNL SQAQQHITTD RTGSHRRQQA YITPTMAQAP YSFPHNSPSH
     GTVHPHLAAA AAAAHLPTQP HLYTYTAPAA LGSTGTVAHL VASQGSARHT VQHTAYPASI
     VHQVPVSMGP RVLPSPTIHP SQYPAQFAHQ TYISASPAST VYTGYPLSPA KVNQYPYI
//
